By Donna Loyle, communications specialist, LIMR
Researchers, including those at Main Line Health, seek to determine the best therapy for patients who’ve been treated for follicular lymphoma but their disease has returned. They are testing how well obinutuzumab (Gazyva®), a monoclonal antibody, works with other drugs.
It’s thought that monoclonal antibodies like obinutuzumab may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination of drugs will work better in treating patients with relapsing or refactory follicular lymphoma.
All study participants are administered obinutuzumab. Participants are then randomized into three study groups that receive the additional drugs as noted below:
- Group 1: umbralisib (TGR-1202), an oral medication currently in clinical trials for blood cancers
- Group 2: lenalidomide (Revlimid®), a cancer drug currently approved to treat myelodysplastic syndrome and multiple myeloma
- Group 3: combination chemotherapy
Study #S1608 is approved for all Main Line Health acute care hospitals. Principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, call 484-476-2649, email email@example.com or visit https://www.mainlinehealth.org/research/clinical-trials/s1608